Newsroom-Katalog
| Zeit | Boehringer Ingelheim: Meldungen vom 27.09.2014 |
|---|---|
| 09:09 | Boehringer Ingelheim's afatinib Achieves Primary Endpoint in Global Phase III Study in Recurrent/Metastatic Head and Neck Squamous Cell Cancer |
| Zeit | Boehringer Ingelheim: Meldungen vom 27.09.2014 |
|---|---|
| 09:09 | Boehringer Ingelheim's afatinib Achieves Primary Endpoint in Global Phase III Study in Recurrent/Metastatic Head and Neck Squamous Cell Cancer |